Microplasmin may eliminate need for surgery

Article

Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.

Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.

The work has been spearheaded by Professor of Ophthalmology at the University of Southampton and consultant ophthalmologist at Southampton Eye Unit, Andrew Lotery and will be trialled at the Wellcome Trust Clinical Research Facility (WTCRF). "Southampton Eye Unit has worked with Wellcome Trust research nurses in 24 studies over the last six years," he said. "This has led to significant research breakthroughs and many patients have had their sight saved by being enrolled in our studies. My research programme would not be possible without the WTCRF."

Director of the WTCRF Dr Saul Faust said: "It is fantastic that the centre is able to support ground breaking research such as Andrew's that has such a positive impact on patient care."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.